Impact of pathogenic germline BRCA1/2 and PALB2 mutations and tumor aneuploidy in patients with HR+/HER2-metastatic breast cancer treated with CDK4/6 inhibitors

被引：0
|
作者：
Antras, Jesus Fuentes
El Ghamrasni, Samah
Zou, Jinfeng
Dou, Aaron
Elliott, Mitchell J.
Avery, Lisa
Bratman, Scott Victor
Cescon, David W.
Bedard, Philippe L.
机构：
[1] Univ Hlth Network, Div Med Oncol & Hematol, Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[3] Princess Margaret Canc Ctr, Toronto, ON, Canada
[4] Univ Toronto, Univ Hlth Network, Dept Biostat, Toronto, ON, Canada
[5] Univ Toronto, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1075
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Multiomic advanced diagnostics for CDK 4/6 drug target activation mapping of HR+/HER2-metastatic breast cancer
    Abu-Khalaf, Maysa M.
    Hatzis, Christos
    Hodge, K. Alex
    Valdes, Frances
    Sikov, William
    Mita, Monica
    Denduluri, Neelima
    Awerkamp, Kris
    Murphy, Rita
    Zelterman, Daniel
    Dunetz, Bryant
    Petricoin, Emanuel
    Pierobon, Mariaelena
    CANCER RESEARCH, 2021, 81 (04)
  • [42] A Survey of BRCA1, BRCA2, and PALB2 mutations in women with breast cancer in Trinidad and Tobago
    Donenberg, Talia
    Ahmed, Humayun
    Royer, Robert
    Zhang, Shiyu
    Narod, Steven A.
    George, Sophia
    Akbari, Mohammad R.
    Ali, Jameel
    Hurley, Judith
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 159 (01) : 131 - 138
  • [43] A Survey of BRCA1, BRCA2, and PALB2 mutations in women with breast cancer in Trinidad and Tobago
    Talia Donenberg
    Humayun Ahmed
    Robert Royer
    Shiyu Zhang
    Steven A. Narod
    Sophia George
    Mohammad R. Akbari
    Jameel Ali
    Judith Hurley
    Breast Cancer Research and Treatment, 2016, 159 : 131 - 138
  • [44] Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland
    P. Wojcik
    M. Jasiowka
    E. Strycharz
    M. Sobol
    D. Hodorowicz-Zaniewska
    P. Skotnicki
    T. Byrski
    P. Blecharz
    E. Marczyk
    I. Cedrych
    J. Jakubowicz
    J. Lubiński
    V. Sopik
    S. Narod
    P. Pierzchalski
    Hereditary Cancer in Clinical Practice, 14
  • [45] Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland
    Wojcik, P.
    Jasiowka, M.
    Strycharz, E.
    Sobol, M.
    Hodorowicz-Zaniewska, D.
    Skotnicki, P.
    Byrski, T.
    Blecharz, P.
    Marczyk, E.
    Cedrych, I.
    Jakubowicz, J.
    Lubinski, J.
    Sopik, V.
    Narod, S.
    Pierzchalski, P.
    HEREDITARY CANCER IN CLINICAL PRACTICE, 2016, 14
  • [46] Cost-effectiveness of CDK4/6 inhibitors in the first-line treatment of HR+/HER2-metastatic breast cancer in postmenopausal women in the United States.
    Masurkar, Prajakta P.
    Damgacioglu, Haluk
    Deshmukh, Ashish
    Trivedi, Meghana
    CANCER RESEARCH, 2021, 81 (13)
  • [47] Germline pathogenic variants in BRCA1, BRCA2, PALB2 and RAD51C in breast cancer women from Argentina
    Cerretini, Roxana
    Mercado, Graciela
    Morganstein, Josh
    Schiaffi, Jorge
    Reynoso, Monica
    Montoya, Diana
    Valdez, Rita
    Narod, Steven A.
    Akbari, Mohammad R.
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 178 (03) : 629 - 636
  • [48] Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2
    Yadav, Siddhartha
    Boddicker, Nicholas J.
    Na, Jie
    Polley, Eric C.
    Hu, Chunling
    Hart, Steven N.
    Gnanaolivu, Rohan D.
    Larson, Nicole
    Holtegaard, Susan
    Huang, Huaizhi
    Dunn, Carolyn A.
    Teras, Lauren R.
    Patel, Alpa V.
    Lacey, James V.
    Neuhausen, Susan L.
    Martinez, Elena
    Haiman, Christopher
    Chen, Fei
    Ruddy, Kathryn J.
    Olson, Janet E.
    John, Esther M.
    Kurian, Allison W.
    Sandler, Dale P.
    O'Brien, Katie M.
    Taylor, Jack A.
    Weinberg, Clarice R.
    Anton-Culver, Hoda
    Ziogas, Argyrios
    Zirpoli, Gary
    Goldgar, David E.
    Palmer, Julie R.
    Domchek, Susan M.
    Weitzel, Jeffrey N.
    Nathanson, Katherine L.
    Kraft, Peter
    Couch, Fergus J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (09) : 1703 - +
  • [49] Efficacy of everolimus in HR+HER2-metastatic breast cancer patients after progression on CDK4/6 inhibitors
    Watanabe, Kenichi
    Kuwahara, Sayuri
    Tachikawa, Hanae
    Maeda, Hideki
    Yamamoto, Mitsugu
    Tomioka, Nobumoto
    Takahashi, Masato
    ANNALS OF ONCOLOGY, 2022, 33 : S538 - S538
  • [50] Composite biomarkers for the prediction of progression-free survival with CDK4/6 inhibitors in metastatic HR+/HER2-breast cancer
    Witkiewicz, Agnieszka
    Wang, Jianxin
    Knudsen, Erik
    Levine, Ellis
    O'Connor, Tracey
    CANCER RESEARCH, 2024, 84 (09)
12345